<DOC>
	<DOCNO>NCT02234921</DOCNO>
	<brief_summary>This pilot study DRibble vaccine patient advanced prostate cancer .</brief_summary>
	<brief_title>Pilot Study DRibble Vaccine Prostate Cancer Patients</brief_title>
	<detailed_description>The primary objective pilot study assess safety tolerability DRibble vaccine , cyclophosphamide , imiquimod , Ceravix castrate resistant prostate cancer . This study also ass : - immune profile tumor biopsy specimens site amenable biopsy present - humoral cellular response cancer antigens DRibble vaccination - response reporter antigen vaccine ( Ceravix ) DRibble vaccination An exploratory objective characterize microbiome study drug administration correlate prostate cancer response .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Subjects measurable evaluable metastatic castrate resistant adenocarcinoma prostate progression chemotherapy , combine androgen blockade and/or peripheral androgen androgen receptor suppression . Either histologic serum marker diagnosis acceptable . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Ability give inform consent comply protocol . Prior therapy investigational agent must complete least 3 week prior study enrollment . Patients must normal organ marrow function determine routine blood test Active autoimmune disease except vitiligo hypothyroidism . Active malignancy . Known HIV positive and/or Hepatitis B C positive . Other medical psychiatric condition opinion Principal Investigator would preclude safe participation protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>DRibble</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Microbiome</keyword>
</DOC>